"Homozygote" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An individual in which both alleles at a given locus are identical.
| Descriptor ID |
D006720
|
| MeSH Number(s) |
G05.380.554
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Homozygote".
Below are MeSH descriptors whose meaning is more specific than "Homozygote".
This graph shows the total number of publications written about "Homozygote" by people in this website by year, and whether "Homozygote" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1997 | 1 | 1 | 2 |
| 1999 | 0 | 4 | 4 |
| 2000 | 2 | 2 | 4 |
| 2002 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 3 | 3 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 1 | 3 |
| 2017 | 2 | 2 | 4 |
| 2018 | 1 | 2 | 3 |
| 2020 | 0 | 4 | 4 |
| 2021 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 2 | 4 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Homozygote" by people in Profiles.
-
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. Lancet Diabetes Endocrinol. 2025 Mar; 13(3):178-187.
-
Ezetimibe in the management of homozygous familial hypercholesterolaemia. J Clin Lipidol. 2025 Mar-Apr; 19(2):320-326.
-
Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. Eur Heart J. 2024 Jul 12; 45(27):2422-2434.
-
Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries. Lancet Child Adolesc Health. 2024 Jul; 8(7):491-499.
-
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arterioscler Thromb Vasc Biol. 2024 May; 44(5):1156-1164.
-
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023 Jul 01; 44(25):2277-2291.
-
Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19. J Clin Lipidol. 2021 Mar-Apr; 15(2):379-380.
-
Evinacumab for Homozygous Familial Hypercholesterolemia. Reply. N Engl J Med. 2021 02 11; 384(6):e17.
-
Autozygosity influences cardiometabolic disease-associated traits in the AWI-Gen sub-Saharan African study. Nat Commun. 2020 11 13; 11(1):5754.
-
Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020 08 20; 383(8):711-720.